N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester | 232615-14-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester
• 英文别名: N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester；tert-butyl N-[(2R)-1-[[(2R)-1-[dimethylamino(methyl)amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-N-methylcarbamate
• CAS: 232615-14-4
• 化学式: C₃₂H₄₂N₄O₄
• 分子量: 546.71
• InChiKey: WJFRSMBPQRTZJV-VSGBNLITSA-N

物化性质

• 沸点：
  682.8±65.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  40
• 可旋转键数：
  11
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  73.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 {(E)-1,1-Dimethyl-4-[methyl-((R)-1-{methyl-[(R)-2-phenyl-1-(N,N',N'-trimethyl-hydrazinocarbonyl)-ethyl]-carbamoyl}-2-naphthalen-2-yl-ethyl)-carbamoyl]-but-3-enyl}-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal

  摘要：

  A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(00)00146-x
• 作为产物：
  描述：

  N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamic acid tert-butyl ester 在 N-甲基吗啉 、 盐酸 、 1-(3-N,N-dimethylaminopropyl)-3-ethylcarbodiimide 、 3-羟基-1,2,3-苯并三嗪-4(3H)-酮 作用下， 以 N,N-二甲基乙酰胺 、 乙酸乙酯 为溶剂， 生成 N-methyl-N-((1R)-1-(N-methyl-N-[(1R)-2-phenyl-1-(N,N',N'-trimethylhydrazinocarbonyl)ethyl]carbamoyl)-2-(2-naphthyl)ethyl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  GH释放化合物NNC 26-1089的合成

  摘要：

  盐酸三甲基肼的合成为多克级合成提供了一种稳定且操作安全的反应物，从而可以制备三肽样的诺和诺德生长激素...

  DOI：

  10.1021/op0200118

文献信息

• Compounds with growth hormone releasing properties
  申请人：Novo Nordisk A/S

  公开号：US06083908A1

  公开（公告）日：2000-07-04

  Compounds of Formula I ##STR1## and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.4a, R.sup.5a, G, J and D are as defined in the specification.

  公开了式I的化合物及其用于治疗由生长激素缺乏引起的医学疾病，其中R.sup.1、R.sup.2、R.sup.3a、R.sup.4a、R.sup.5a、G、J和D如规范中所定义。
• COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
  申请人：NOVO NORDISK A/S

  公开号：EP1047709B1

  公开（公告）日：2004-11-03
• US6083908A
  申请人：——

  公开号：US6083908A

  公开（公告）日：2000-07-04
• Growth hormone secretagogues derived from NN703 with hydrazidesas c-terminal
  作者：Michael Ankersen、Karin Kramer Nielsen、Thomas Kruse Hansen、Kirsten Raun、Birgit Sehested Hansen

  DOI：10.1016/s0223-5234(00)00146-x

  日期：2000.5

  A series of GH secretagogues based on modifications in the C-terminal of NN703 is reported. The C-terminal N-methyl amide of NN703 has been replaced with alkylated hydrazides in order to decrease the volume of distribution and identify GH secretagogues with shorter duration of action. Most of the prepared compounds show high potency in a rat pituitary assay. Subsequent to an initial in vivo screening in dogs, four compounds were selected for further pharmacological and pharmacokinetic evaluation. The four compounds showed oral bioavailability around 35% and equipotency in vitro compared to NN703. The relationship between lipophilicity and volume of distribution is discussed and it is speculated whether the lower volume of distribution is attributed to the observed higher in vivo potency and shorter plasma elimination half-life. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
• The Synthesis of a GH-Releasing Compound NNC 26-1089
  作者：Peter Andersen、Michael Ankersen、Claus Ulrich Jessen、Søren Vig Lehman

  DOI：10.1021/op0200118

  日期：2002.7.1

  The synthesis of trimethylhydrazine hydrochloride provides a stable and safe-to-handle reactant for multigram-scale synthesis making the preparation of the tripeptidelike Novo Nordisk growth hormon...

  盐酸三甲基肼的合成为多克级合成提供了一种稳定且操作安全的反应物，从而可以制备三肽样的诺和诺德生长激素...